Collectively, these multifaceted actions establish GLP-1 RAs as potent agents for vascular protection, making them an attractive therapeutic option for patients with T2DM at risk of PAD and other cardiovascular complications. The gene discussed is GLP1R; the disease is peripheral arterial disease.